NZ719268A - Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction - Google Patents

Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction Download PDF

Info

Publication number
NZ719268A
NZ719268A NZ719268A NZ71926814A NZ719268A NZ 719268 A NZ719268 A NZ 719268A NZ 719268 A NZ719268 A NZ 719268A NZ 71926814 A NZ71926814 A NZ 71926814A NZ 719268 A NZ719268 A NZ 719268A
Authority
NZ
New Zealand
Prior art keywords
cranberry
acid
oral dosage
solid oral
weight
Prior art date
Application number
NZ719268A
Other languages
English (en)
Inventor
Emilie Fromentin
Douglas Klaiber
Daniel Souza
Original Assignee
Naturex Dbs Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53042226&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ719268(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Naturex Dbs Llc filed Critical Naturex Dbs Llc
Publication of NZ719268A publication Critical patent/NZ719268A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ719268A 2013-11-11 2014-11-11 Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction NZ719268A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361902376P 2013-11-11 2013-11-11
PCT/US2014/064961 WO2015070203A1 (en) 2013-11-11 2014-11-11 Compositions and methods useful in treatment of lower urinary tract sysptoms, benign prostatic hyperplasia, erectile dysfunction

Publications (1)

Publication Number Publication Date
NZ719268A true NZ719268A (en) 2021-07-30

Family

ID=53042226

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ719268A NZ719268A (en) 2013-11-11 2014-11-11 Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction

Country Status (21)

Country Link
US (5) US20160324911A1 (ja)
EP (2) EP3782634B1 (ja)
JP (2) JP6966196B2 (ja)
KR (2) KR20230004886A (ja)
CN (2) CN105848663A (ja)
AU (1) AU2014346415B2 (ja)
BR (1) BR112016010509B1 (ja)
CA (1) CA2928631A1 (ja)
CL (1) CL2016001109A1 (ja)
CR (1) CR20160254A (ja)
ES (1) ES2860773T3 (ja)
IL (1) IL245552B (ja)
MX (1) MX2016005810A (ja)
MY (1) MY184225A (ja)
NZ (1) NZ719268A (ja)
PH (1) PH12016500780A1 (ja)
PL (1) PL3068414T3 (ja)
RU (1) RU2696584C1 (ja)
SG (2) SG10201910781SA (ja)
WO (1) WO2015070203A1 (ja)
ZA (1) ZA201602941B (ja)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014346415B2 (en) * 2013-11-11 2020-04-23 Naturex-Dbs Llc Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction
JP6412291B1 (ja) * 2017-01-20 2018-10-24 マルカイコーポレーション株式会社 頻尿の改善剤
CN107647387A (zh) * 2017-08-15 2018-02-02 孟广千 用于补膀胱的保健食品
IT201800007473A1 (it) 2018-07-24 2020-01-24 Sistema di aggancio ad evidenza di manomissione, procedimento per la realizzazione di detto sistema di aggancio, contenitore comprendente detto sistema di aggancio ed uso di quest'ultimo
JP7219907B2 (ja) * 2018-07-25 2023-02-09 株式会社 沖縄リサーチセンター 下部尿路症状改善用組成物
JP6738388B2 (ja) * 2018-09-27 2020-08-12 マルカイコーポレーション株式会社 頻尿の改善剤
WO2021091322A1 (ko) * 2019-11-08 2021-05-14 씨제이제일제당 (주) 폴리페놀을 포함하는 조성물
JP2023539638A (ja) * 2020-08-31 2023-09-15 コングク ユニバーシティ グローカル インダストリー－アカデミック コラボレーション ファウンデーション ウチワノキ抽出物を有効成分として含むアンドロゲン受容体関連疾患治療用薬学的組成物
WO2022189010A1 (en) * 2021-03-07 2022-09-15 Givaudan Sa Methods and compositions for treating and preventing urinary tract infections
KR102388984B1 (ko) * 2021-11-16 2022-04-20 재단법인 전남바이오산업진흥원 모새나무 열매 추출물을 유효성분으로 포함하는 전립선 비대증 예방 또는 치료용 약학조성물

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5525341A (en) * 1992-10-09 1996-06-11 Jlb, Inc. Partially purified cranberry anti-adhesion activity
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6231866B1 (en) * 1998-04-30 2001-05-15 Douglas G. Mann Infused vegetable, fruit, herb, and/or seed fiber product and dietary supplements containing same
US20010025059A1 (en) 2000-01-10 2001-09-27 Kastke Floyd A. Composition and method for treating non-bacterial prostatitis
US6391345B1 (en) 2000-05-12 2002-05-21 Tim Heeg Cranberry seed oil, cranberry seed flour and a method for making
WO2005107476A2 (en) * 2004-05-03 2005-11-17 Northern Lights Food Processing, Llc Berry oils and products
JP2001342142A (ja) * 2000-06-01 2001-12-11 Nissui Pharm Co Ltd 泌尿器系疾患予防治療用組成物
US7270837B2 (en) * 2003-11-10 2007-09-18 Rutgers, The State University Of New Jersey Anti-inflammatory cranberry flavonol extract preparations
CA2555121A1 (en) * 2004-02-04 2005-08-25 Foamix Ltd. Cosmetic and pharmaceutical foam with solid matter
US8153166B2 (en) * 2006-06-08 2012-04-10 Chih-Hsiung Lin Composition for prophylaxis or treatment of urinary system infection and method thereof
JP2010531174A (ja) * 2007-06-27 2010-09-24 コロプラスト アクティーゼルスカブ サポニンと抗生物質の混合物による尿路感染症の治療
CN101095764B (zh) * 2007-07-13 2010-05-19 天津天狮生物发展有限公司 具有辅助治疗女性泌尿道感染的保健食品
US8173178B1 (en) 2007-08-03 2012-05-08 Decas Botanical Synergies, Llc Compositions and methods for controlling metabolic syndrome using whole fruit-derived cranberry ingredient profile enriched in stress adapted bioactives (SABs)
US20090175843A1 (en) * 2008-01-08 2009-07-09 Medical Nutrition Usa, Inc. Composition for prevention or treatment of urinary tract infection
US20090180999A1 (en) * 2008-01-11 2009-07-16 U.S. Nutraceuticals, Llc D/B/A Valensa International Method of preventing, controlling and ameliorating urinary tract infections using cranberry derivative and d-mannose composition
US20110064706A1 (en) 2008-01-11 2011-03-17 U.S. Nutraceuticals, Llc D/B/A Valensa International Method of preventing, controlling and ameliorating urinary tract infections and supporting digestive health by using a synergistic cranberry derivative, a d-mannose composition and a proprietary probiotic blend
EP2156835A1 (en) * 2008-08-19 2010-02-24 Sanofi-Aventis New therapeutic use of drotaverine
CN102781928B (zh) 2010-01-15 2016-05-18 优鲜沛蔓越莓公司 用于从酸果蔓叶子提取化合物的方法及相关产品
CN101999648B (zh) * 2010-10-11 2012-10-31 宝鸡市虹源生物科技有限公司 蔓越橘果实中花色苷及原花青素类成分的提取方法
JP2012171899A (ja) * 2011-02-21 2012-09-10 Unitika Ltd 尿路感染症予防改善剤
FR2972328A1 (fr) * 2011-03-07 2012-09-14 Walmark A S Complement alimentaire augmentant la protection de l'epithelium des voies urinaires basses contre les infections a repetition
US20130122146A1 (en) * 2011-11-16 2013-05-16 Decas Botanical Synergies, Llc Process for Spray Drying Botanical Food
AU2014346415B2 (en) * 2013-11-11 2020-04-23 Naturex-Dbs Llc Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction

Also Published As

Publication number Publication date
US20190358282A1 (en) 2019-11-28
US20180256663A1 (en) 2018-09-13
CL2016001109A1 (es) 2016-12-02
SG11201603462SA (en) 2016-05-30
SG10201910781SA (en) 2020-01-30
PH12016500780B1 (en) 2016-06-13
BR112016010509A2 (pt) 2017-08-08
EP3782634B1 (en) 2024-03-20
KR20160079884A (ko) 2016-07-06
EP3068414A1 (en) 2016-09-21
KR20230004886A (ko) 2023-01-06
EP3782634A1 (en) 2021-02-24
AU2014346415A1 (en) 2016-05-12
JP2020059725A (ja) 2020-04-16
ES2860773T3 (es) 2021-10-05
IL245552B (en) 2020-07-30
JP6966196B2 (ja) 2021-11-10
CN105848663A (zh) 2016-08-10
PL3068414T3 (pl) 2021-08-30
MY184225A (en) 2021-03-28
WO2015070203A1 (en) 2015-05-14
JP7083330B2 (ja) 2022-06-10
RU2016122062A (ru) 2017-12-19
US20160324911A1 (en) 2016-11-10
US20220175863A1 (en) 2022-06-09
US11291703B2 (en) 2022-04-05
IL245552A0 (en) 2016-06-30
US10898534B2 (en) 2021-01-26
WO2015070203A9 (en) 2016-01-14
CR20160254A (es) 2016-08-31
US11045511B2 (en) 2021-06-29
JP2016539183A (ja) 2016-12-15
PH12016500780A1 (en) 2016-06-13
MX2016005810A (es) 2016-11-18
RU2696584C1 (ru) 2019-08-05
EP3068414B1 (en) 2020-12-30
AU2014346415B2 (en) 2020-04-23
US20200121750A1 (en) 2020-04-23
EP3068414A4 (en) 2017-06-07
CA2928631A1 (en) 2015-05-14
CN116077548A (zh) 2023-05-09
BR112016010509B1 (pt) 2021-08-17
KR102476969B1 (ko) 2022-12-12
ZA201602941B (en) 2022-05-25

Similar Documents

Publication Publication Date Title
US10898534B2 (en) Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction and other diseases or symptoms
Singh et al. Health benefits of resveratrol: Evidence from clinical studies
Parafati et al. Bergamot polyphenol fraction prevents nonalcoholic fatty liver disease via stimulation of lipophagy in cafeteria diet-induced rat model of metabolic syndrome
Aiyer et al. Influence of berry polyphenols on receptor signaling and cell-death pathways: implications for breast cancer prevention
Cechinel-Zanchett et al. Diuretic and renal protective effect of kaempferol 3-O-alpha-l-rhamnoside (afzelin) in normotensive and hypertensive rats
Greyling et al. Effects of wine and grape polyphenols on blood pressure, endothelial function and sympathetic nervous system activity in treated hypertensive subjects
US11857510B2 (en) Methods and compositions for treating congenital diarrhea disorder
JP2019504117A (ja) 前立腺過形成の処置のための医薬組成物
Wickramasinghe et al. Herbal extracts encapsulated nanoliposomes as potential glucose-lowering agents: An in vitro and in vivo approach using three herbal extracts
Eid et al. Lingonberry (vacciniumvitis-idaea L) mobilizes L6 muscle GLUT4 transporters and exerts anti-obesity and antidiabetic effects in vivo
CN103945857A (zh) 用于治疗代谢疾病、心血管疾病、以及炎症的蝶芪和他汀组合
US20130149277A1 (en) Pterostilbene and pvp grape juice extract combination for treatment of metabolic, vascular, and neurodegenerative disorders
Aloud Effects of cyanidin 3-O-glucoside on cardiovascular complications and immune response in spontaneously hypertensive rats
Sowa-Kucma et al. Lihong Ye1, Jiayi Wu2, Zuyi Liu1, Di Deng1, Shasha Bai1, Lei Yang1, Yao Xuan1, Zehao Liu1, Yafei Shi2, Zhongqiu Liu1, Rong Zhang1* and Jinlan Zhao1
Claassen Investigating the parts to understand the whole: Contribution of phenolic compounds to the desired estrogenic activity of SM6Met fractions from Cyclopia subternata
KR20240001176A (ko) 다낭성 난소 증후군 관리용 조성물
CN110237066A (zh) 3-甲氧基黄酮及其衍生物在制备治疗或预防肾病的药物中的应用
Petersen Strawberry Supplementation Lessens Vascular Inflammation and Dysfunction Displayed by db/db Mice
Knights et al. 13 Drug and Nutrient Interactions

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: NATUREX-DBS LLC, US

Effective date: 20160505

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 NOV 2023 BY DENNEMEYER + CO.

Effective date: 20221101

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 NOV 2024 BY DENNEMEYER + CO.

Effective date: 20231031